Spago Nanomedical's pegfosimer manganese demonstrated successful contrast enhancement in breast cancer MRI imaging with acceptable safety profile in the SPAGOPIX-01 clinical trial. The findings, set to be published in Investigative Radiology, mark a significant advancement in precision medical imaging for cancer diagnostics.